NCT04095286 - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

December 17, 2019

Study Completion Date

December 17, 2019

Conditions

Hypertension, Pulmonary

Interventions

DRUG

AMB new formulation (1 mg)

AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.

DRUG

Reference AMB (5 mg)

AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge